GlassScriptPhysician profile
Thomas G Lammy
NPI 1982653242
$4,784.26
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,125 · 2020: $1,091 · 2021: $1,147 · 2022: $842 · 2023: $370 · 2024: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $579.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $578.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $671.41 | 2019-2023 | Emgality, Jardiance |
| Amgen INC. | $627.50 | 2019-2023 | Otezla, Repatha |
| Novo Nordisk INC | $612.62 | 2019-2021 | |
| Radius Health, INC. | $374.05 | 2019-2022 | |
| Abbvie INC. | $342.91 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $280.03 | 2019-2024 | Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $211.46 | 2023-2024 | Lybalvi |
| Astellas Pharma US INC | $191.81 | 2019-2023 | Myrbetriq |
| Pfizer INC. | $191.09 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $183.21 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $167.14 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.39 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $118.43 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $78.42 | 2021-2022 | |
| Antares Pharma, INC. | $77.18 | 2020-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $75.89 | 2020-2021 | |
| Amarin Pharma, INC. | $71.20 | 2020 | |
| Janssen Pharmaceuticals, INC | $66.36 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $61.25 | 2020-2021 | |
| Glaxosmithkline, LLC. | $42.99 | 2021-2022 | |
| Eisai INC. | $35.36 | 2021 | |
| Medtronic, INC. | $34.93 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.93 | 2021-2022 | |
| Cardiovascular Systems INC. | $22.26 | 2019 | |
| Janssen Biotech, INC. | $18.84 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $17.94 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $16.86 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $12.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Lammy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.